| Literature DB >> 1751456 |
W J Power1, A Benedict-Smith, M Hillery, K Brady, L M Collum.
Abstract
The results of a randomised double-blind clinical trial of 0.1% bromovinyldeoxyuridine (BVDU) and 1% trifluorothymidine (TFT) in 60 patients with corneal dendritic ulceration are presented. There was no significant difference between BVDU and TFT in terms of numbers of ulcers healed (p = 0.61), mean healing time (p = 0.065), and cumulative healing rate (p = 0.058). No serious side effects were observed, though transient stinging was recorded in five patients receiving TFT and in three patients receiving BVDU. One patient in the group treated with TFT developed a punctate epitheliopathy.Entities:
Mesh:
Substances:
Year: 1991 PMID: 1751456 PMCID: PMC1042518 DOI: 10.1136/bjo.75.11.649
Source DB: PubMed Journal: Br J Ophthalmol ISSN: 0007-1161 Impact factor: 4.638